Steven A. Baker, MD, PhD

Steven A. Baker, MD, PhD

Associate Medical Director: Transfusion Medicine

Assistant Professor, University of Utah School of Medicine

Specialties

  • Transfusion Medicine

Education

  • Medical Degree—Baylor College of Medicine
  • Doctor of Philosophy—Baylor College of Medicine
  • Residency—Clinical Pathology, Stanford University School of Medicine
  • Fellowship—Transfusion Medicine, Stanford University School of Medicine

Certifications/Affiliations

  • American Board of Pathology (Clinical Pathology)

Research Interests

  •  Transfusion medicine
  •  Blood coagulation

Recent Publications

Wawro AM, et al. Enantiomers of 2-methylglutamate and 2-methylglutamine selectively impact mouse brain metabolism and behavior. Sci Rep. 2021;11(1):8138.

Wawro AM, et al. Creatine transport and pathological changes in creatine transporter deficient mice. J Inherit Metab Dis. 2021;44(4):939-48.

Baker SA, et al. Angiotensin-converting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation. PLoS One. 2021;16(2):e0247060.

Baker SA, et al. DOAC-Stop permits the safe and effective removal of direct oral anticoagulant interference in lupus anticoagulant testing. Res Pract Thromb Haemost. 2021;5(2):314-25.

Ito-Ishida A, et al. MeCP2 levels regulate the 3D structure of heterochromatic foci in mouse neurons. J Neuroscience. 2020;40(45):8746-66.

Jin J, et al. Implementation of whole-blood impedance aggregometry for heparin-induced thrombocytopenia functional assay and case discussion. Am J Clin Pathol. 2019;152(1):50-8.

Ito-Ishida A, et al. Genome-wide distribution of linker histone H1.0 is independent of MeCP2. Nat Neurosci. 2018;21(6):794-8.

Shah N, et al. Real-time clinical decision support decreases inappropriate plasma transfusion. Am J Clin Pathol. 2017;148(2):154-60.

Lombardi LM, et al. An RNA interference screen identifies druggable regulators of MeCP2 stability. Sci Transl Med. 2017;9(404):eaaf7588.